Our Pipeline

Diverse Pipeline of First-in-Class Aesthetic and Dermatological Solutions

Veradermics is advancing a robust pipeline of product candidates designed to address high-value dermatologic conditions with limited proven solutions, combining proven mechanisms with innovative formulations intended to optimize efficacy, safety, and patient convenience, starting with pattern hair loss – a condition impacting over 80 million people in the US alone.*

Vector
Vector
Vector

PROGRAM INDICATION

MOA Delivery

PRE-IND

PHASE 1

PHASE 2

PHASE 3

Program Indication

VDPHL01
Pattern Hair Loss
(Androgenetic Alopecia)

MOA Delivery

Minoxidil Extended-Release Oral Tablet

PRE-INDPHASE 1PHASE 2PHASE 3

Phase 3 Trials Ongoing - Male and Femaie

*Source: MedlinePlus.gov – Genetics, Androgenetic Alopecia, July 2023: 50M Men, 30M Women

Footer Shape
Pattern Hair Loss